Galecto's listing in the US stock exchange has lead to some changes for the Danish biotech firm.
The people behind the Danish Capital fund Sunstone Life Science recently stepped out of its board and it seems Galecto has found their replacement. Because Galecto has announced that it has gained a new member of the board in Jayson Dallas.
Most recently, Jayson Dallas was the Presiden & CEO at the biotech Aimmune Therapeutics, which has garnered attention for its work towards finding a treatment for peanut allergy. The company was sold to Nestlé's health division earlier in the year, after which Jayson Dallas also left the firm.
I am delighted to welcome Jayson to the Galecto Board of Directors. His expertise in all aspects of the healthcare industry, from biotech to big pharma and drug development to commercialization, will be an important source of knowledge and guidance for Galecto as we continue through an exciting period of growth."
After Galecto became listed on the stock exchange, the firm has found a solid financial foundation – shortly before getting listed, the company fetched some money from private investors – and as such the firm expects to start all of three phase II trials in the next couple of months.
Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.
New Nordic fund prone for second investment – pours millions into antiviral spinout
Venture veterans raise EUR 76 million for new life science fund
Novo Seeds partner wants to raise millions for Nordic life science: "There is a dire need"
More from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Chemist for Incoming Materials in QC Department 
Analytical Coordinator for Analytical Development 
Senior QA Specialist 
2 Sales Representatives and Product Specialists 
Production Director 
Senior Manager, Clinical Trial Budget 
Communications Consultant 
Client Talent Acquisition Specialist 
Nordic Medical Affairs Manager 
Innovation Project Manager, Display Unit 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Account Manager 
Director for innovative pre-clinical testing unit 
Key Account Manager, Europe and Asia 
Senior Chemical Safety Advisor